Recommended Topic Related To:

Tikosyn

"How long a young adult is obese may affect that person's heart disease risk in middle age, according to new research. The finding suggests that not only preventing but also delaying the onset of obesity can help reduce heart disease later in life"...

Tikosyn

Tikosyn Side Effects Center

Medical Editor: John P. Cunha, DO, FACOEP

Tikosyn (dofetilide) is used to help keep the heart beating normally in people with certain heart rhythm disorders of the atrium (the upper chambers of the heart). Tikosyn is used in people with atrial fibrillation or atrial flutter. It is an antiarrhythmic drug. Common side effects include headache, dizziness, or nausea.

The usual recommended dose of Tikosyn is 500 mcg twice daily. When starting, restarting, or increasing the dose, you will need to stay in the hospital for at least 3 days for monitoring. Tikosyn may interact with diuretics (water pills), HIV/AIDS medicine, drugs that can affect heart rhythm, narcotics, antibiotics, antidepressants, medicines to treat psychiatric disorders, or heart rhythm medicine. Tell your doctor all medications you are taking. During pregnancy, Tikosyn should be used only when prescribed. It is unknown if this drug passes into breast milk. Consult your doctor before breast-feeding.

Our Tikosyn (dofetilide) Side Effects Drug Center provides a comprehensive view of available drug information on the potential side effects when taking this medication.

This is not a complete list of side effects and others may occur. Call your doctor for medical advice about side effects. You may report side effects to FDA at 1-800-FDA-1088.

What is Patient Information in Detail?

Easy-to-read and understand detailed drug information and pill images for the patient or caregiver from Cerner Multum.

Tikosyn in Detail - Patient Information: Side Effects

Get emergency medical help if you have any of these signs of an allergic reaction: hives; difficult breathing; swelling of your face, lips, tongue, or throat.

Call your doctor at once if you have a serious side effect such as:

  • headache with chest pain and severe dizziness;
  • fast or pounding heartbeats, feeling like you might pass out;
  • low magnesium (confusion, uneven heart rate, jerking muscle movements, muscle weakness or limp feeling); or
  • low potassium (confusion, uneven heart rate, extreme thirst, increased urination, leg discomfort, muscle weakness or limp feeling).

Less serious side effects may include:

  • mild headache;
  • mild dizziness;
  • sleep problems (insomnia);
  • back pain;
  • nausea, diarrhea, stomach pain;
  • cold symptoms such as stuffy nose, sneezing, sore throat; or
  • mild skin rash.

This is not a complete list of side effects and others may occur. Call your doctor for medical advice about side effects. You may report side effects to FDA at 1-800-FDA-1088.

Read the entire detailed patient monograph for Tikosyn (Dofetilide) »

What is Patient Information Overview?

A concise overview of the drug for the patient or caregiver from First DataBank.

Tikosyn Overview - Patient Information: Side Effects

SIDE EFFECTS: Headache, dizziness, or nausea may occur. If any of these effects persist or worsen, tell your doctor or pharmacist promptly.

Remember that your doctor has prescribed this medication because he or she has judged that the benefit to you is greater than the risk of side effects. Many people using this medication do not have serious side effects.

Seek immediate medical attention if any of these rare but serious side effects occur: chest pain, fainting, faster/more irregular heartbeat, severe dizziness.

A very serious allergic reaction to this drug is rare. However, seek immediate medical attention if you notice any symptoms of a serious allergic reaction, including: rash, itching/swelling (especially of the face/tongue/throat), severe dizziness, trouble breathing.

This is not a complete list of possible side effects. If you notice other effects not listed above, contact your doctor or pharmacist.

In the US -

Call your doctor for medical advice about side effects. You may report side effects to FDA at 1-800-FDA-1088.

In Canada - Call your doctor for medical advice about side effects. You may report side effects to Health Canada at 1-866-234-2345.

Read the entire patient information overview for Tikosyn (Dofetilide)»

What is Prescribing information?

The FDA package insert formatted in easy-to-find categories for health professionals and clinicians.

Tikosyn FDA Prescribing Information: Side Effects
(Adverse Reactions)

SIDE EFFECTS

The TIKOSYN clinical program involved approximately 8,600 patients in 130 clinical studies of normal volunteers and patients with supraventricular and ventricular arrhythmias. TIKOSYN was administered to 5,194 patients, including two large, placebo-controlled mortality trials (DIAMOND CHF and DIAMOND MI) in which 1,511 patients received TIKOSYN for up to three years.

In the following section, adverse reaction data for cardiac arrhythmias and non-cardiac adverse reactions are presented separately for patients included in the supraventricular arrhythmia development program and for patients included in the DIAMOND CHF and MI mortality trials (see Clinical Studies, Safety in Patients with Structural Heart Disease, DIAMOND Studies, for a description of these trials).

In studies of patients with supraventricular arrhythmias, a total of 1,346 and 677 patients were exposed to TIKOSYN and placebo for 551 and 207 patient years, respectively. A total of 8.7% of patients in the dofetilide groups were discontinued from clinical trials due to adverse events compared to 8.0% in the placebo groups. The most frequent reason for discontinuation ( > 1%) was ventricular tachycardia (2.0% on dofetilide vs. 1.3% on placebo). The most frequent adverse events were headache, chest pain, and dizziness.

Serious Arrhythmias And Conduction Disturbances

Torsade de Pointes is the only arrhythmia that showed a dose-response relationship to TIKOSYN treatment. It did not occur in placebo treated patients. The incidence of Torsade de Pointes in patients with supraventricular arrhythmias was 0.8% (11/1346) (see WARNINGS). The incidence of Torsade de Pointes in patients who were dosed according to the recommended dosing regimen (see DOSAGE AND ADMINISTRATION) was 0.8% (4/525). Table 6 shows the frequency by randomized dose of serious arrhythmias and conduction disturbances reported as adverse events in patients with supraventricular arrhythmias.

Table 6: Incidence of Serious Arrhythmias and Conduction Disturbances in Patients with Supraventricular Arrhythmias

Arrhythmia event: TIKOSYN Dose Placebo
N=677
< 250 mcg BID
N=217
250 mcg BID
N=388
> 250-500 mcg BID
N=703
> 500 mcg BID
N=38
Ventricular arrhythmias* ^ 3.70% 2.60% 3.40% 15.80% 2.70%
  Ventricular fibrillation 0 0.30% 0.40% 2.60% 0.10%
  Ventricular tachycardia^ 3.70% 2.60% 3.30% 13.20% 2.50%
    Torsade de Pointes 0 0.30% 0.90% 10.50% 0
Various forms of block
  AV block 0.90% 1.50% 0.40% 0 0.30%
  Bundle branch block   0 0.50% 0.10% 0 0.10%
  Heart block 0 0.50% 0.10% 0 0.10%
* Patients with more than one arrhythmia are counted only once in this category.
^ Ventricular arrhythmias and ventricular tachycardia include all cases of Torsade de Pointes.

In the DIAMOND trials, a total of 1,511 patients were exposed to TIKOSYN for 1757 patient years. The incidence of Torsade de Pointes was 3.3% in CHF patients and 0.9% in patients with a recent MI.

Table 7 shows the incidence of serious arrhythmias and conduction disturbances reported as adverse events in the DIAMOND subpopulation that had AF at entry to these trials.

Table 7: Incidence of Serious Arrhythmias and Conduction Disturbances in Patients with AF at Entry to the DIAMOND Studies

  TIKOSYN
N=249
Placebo
N=257
Ventricular arrhythmias* ^ 14.50% 13.60%
  Ventricular fibrillation    4.80% 3.10%
  Ventricular tachycardia^ 12.40% 11.30%
    Torsade de Pointes 1.60% 0
Various forms of block
  AV block 0.80% 2.70%
  (Left) bundle branch block 0 0.40%
  Heart block 1.20% 0.80%
* Patients with more than one arrhythmia are counted only once in this category.
^ Ventricular arrhythmias and ventricular tachycardia include all cases of Torsade de Pointes.

Other Adverse Reactions

Table 8 presents other adverse events reported with a frequency of > 2% on TIKOSYN and reported numerically more frequently on TIKOSYN than on placebo in the studies of patients with supraventricular arrhythmias.

Table 8: Frequency of Adverse Events Occurring at > 2% on TIKOSYN, and Numerically More Frequently on TIKOSYN than Placebo in Patients with Supraventricular Arrhythmias

Adverse Event TIKOSYN
%
Placebo
%
headache 11 9
chest pain 10 7
dizziness 8 6
respiratory tract infection 7 5
dyspnea 6 5
nausea 5 4
flu syndrome 4 2
insomnia 4 3
accidental injury 3 1
back pain 3 2
procedure (medical/surgical/health service) 3 2
diarrhea 3 2
rash 3 2
abdominal pain 3 2

Adverse events reported at a rate > 2% but no more frequently on TIKOSYN than on placebo were: angina pectoris, anxiety, arthralgia, asthenia, atrial fibrillation, complications (application, injection, incision, insertion, or device), hypertension, pain, palpitation, peripheral edema, supraventricular tachycardia, sweating, urinary tract infection, ventricular tachycardia.

The following adverse events have been reported with a frequency of < 2% and numerically more frequently with TIKOSYN than placebo in patients with supraventricular arrhythmias: angioedema, bradycardia, cerebral ischemia, cerebrovascular accident, edema, facial paralysis, flaccid paralysis, heart arrest, increased cough, liver damage, migraine, myocardial infarct, paralysis, paresthesia, sudden death, and syncope.

The incidences of clinically significant laboratory test abnormalities in patients with supraventricular arrhythmias were similar for patients on TIKOSYN and those on placebo. No clinically relevant effects were noted in serum alkaline phosphatase, serum GGT, LDH, AST, ALT, total bilirubin, total protein, blood urea nitrogen, creatinine, serum electrolytes (calcium, chloride, glucose, magnesium, potassium, sodium), or creatine kinase. Similarly, no clinically relevant effects were observed in hematologic parameters.

In the DIAMOND population, adverse events other than those related to the post-infarction and heart failure patient population were generally similar to those seen in the supraventricular arrhythmia groups.

Read the entire FDA prescribing information for Tikosyn (Dofetilide) »

A A A

Tikosyn - User Reviews

Tikosyn User Reviews

Now you can gain knowledge and insight about a drug treatment with Patient Discussions.

Here is a collection of user reviews for the medication Tikosyn sorted by most helpful. Patient Discussions FAQs

Report Problems to the Food and Drug Administration

 

You are encouraged to report negative side effects of prescription drugs to the FDA. Visit the FDA MedWatch website or call 1-800-FDA-1088.


Heart Health

Get the latest treatment options.